APP and cancer: The results indicate that activating LXR with the ligand GW3965 or the FDA-approved antiskin cancer drug bexarotene reduces soluble and insoluble Aβ and improves cognition in APP Tg mice, while knocking out the ABCA1 gene in APP mice showed a tendency to reduced amyloid load.